00:08 , May 26, 2016 |  BC Extra  |  Company News

Vitesse launches first newco Thunderbolt

Vitesse Biologics LLC (South San Francisco, Calif.) launched virtual newco Thunderbolt Pharma Inc. (South San Francisco, Calif.), which will house a preclinical dual antagonist program targeting BLyS (BAFF) and tumor necrosis factor (TNF) ligand superfamily...
07:00 , Oct 12, 2015 |  BC Week In Review  |  Financial News

Opsonix completes venture financing

Opsonix Inc. , Cambridge, Mass.   Business: Infectious   Date completed: 2015-10-08   Type: Venture financing   Raised: $8 million   Investors: Baxter Ventures; private investor  ...
07:00 , Sep 21, 2015 |  BC Week In Review  |  Financial News

Aptinyx completes venture financing

Aptinyx Inc. , Chicago, Ill.   Business: Neurology   Date completed: 2015-09-16   Type: Venture financing   Raised: Not disclosed   Investors: Cowen; EcoR1 Capital; Goudy Park Capital; Portola Capital Partners; Sabby Capital; Adams Street...
07:00 , Sep 14, 2015 |  BC Week In Review  |  Financial News

Sanifit completes venture financing

Laboratoris Sanifit S.L. , Palma de Mallorca, Spain   Business: Cardiovascular, Renal, Musculoskeletal   Date completed: 2015-09-08   Type: Venture financing   Raised: EUR36.6 million ($40.8 million)   Investors: Ysios Capital Partners; Lundbeckfond Ventures; Forbion...
07:00 , Jul 13, 2015 |  BioCentury  |  Strategy

Baxalta's blueprint

Now that Baxalta Inc. has completed its spinout from Baxter International Inc. , the newco's ambitious plan is to launch 20 new drugs, including line extensions, by 2020. The products, which come from a mix...
07:00 , Jun 8, 2015 |  BC Week In Review  |  Company News

Velocity Pharmaceutical Development, Vitesse Biologics, Baxter, Mayo Clinic deal

Baxter’s Baxter Ventures arm, the Mayo Clinic and Velocity Pharmaceutical formed Vitesse Biologics, a newco that will develop antibody and protein-based therapies for immunology, hematology and oncology. Baxter’s BioScience unit, which is spinning out this...
01:44 , Jun 2, 2015 |  BC Extra  |  Company News

Baxter, Velocity, Mayo Clinic create Vitesse

The Baxter Ventures arm of Baxter International Inc. (NYSE:BAX), the Mayo Clinic (Rochester, Minn.) and Velocity Pharmaceutical Development (South San Francisco, Calif.) formed Vitesse Biologics LLC (South San Francisco, Calif.), a newco that intends to...
07:00 , May 18, 2015 |  BC Week In Review  |  Financial News

Precision BioSciences completes venture financing

Precision BioSciences Inc. , Durham, N.C.   Business: Genomics   Date completed: 2015-05-11   Type: Venture financing   Raised: $25.6 million   Investors: VenBio LLC; Fidelity Biosciences; Amgen Ventures; Baxter Ventures; Osage University Partners; The...
02:17 , May 12, 2015 |  BC Extra  |  Financial News

Precision raises $25.6M in series A

Gene editing company Precision BioSciences Inc. (Durham, N.C.) raised $25.6 million in a series A round led by venBio. Other investors included Fidelity Biosciences; Amgen Ventures; Baxter Ventures; Osage University Partners; The Longevity Fund; and...
07:00 , May 4, 2015 |  BC Week In Review  |  Financial News

Mirna completes venture financing

Mirna Therapeutics Inc. , Austin, Texas   Business: Cancer   Date completed: 2015-04-30   Type: Venture financing   Raised: $41.8 million   Investors: Baxter Ventures; Eastern Capital; Sante Ventures LLC; Morningside Venture Investments; Rock Springs...